Cost-effectiveness of novel vaccines for tuberculosis control: A decision analysis study

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Tseng, Chia Lin ^a,b   Oxlade, Olivia ^a,c   Menzies, Dick ^a,c   Aspler, Anne ^d   Schwartzman, Kevin ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DIRECTLY OBSERVED THERAPY; DRUG EFFECT; ECONOMICS; HEALTH CARE COST; HUMAN; INFANT; INFECTION CONTROL; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; PRESCHOOL CHILD; STATISTICS; TUBERCULOSIS; ZAMBIA;

ADOLESCENT; ADULT; BCG VACCINE; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIRECTLY OBSERVED THERAPY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INFANT; INFANT, NEWBORN; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; YOUNG ADULT; ZAMBIA;

EID: 79251572945     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-55     Document Type: Article

References (93)

1. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009 Geneva: WHO Press; 2009.
2. Meulemans H, Mortelmans D, Liefooghe R, Mertens P, Zaidi SA, Solangi MF, De Muynck A: The limits to patient compliance with directly observed therapy for tuberculosis: a socio-medical study in Pakistan. Int J Health Plann Manage 2002, 17:249-267. (Pubitemid 34993581)
3. Elzinga G, Raviglione MC, Maher D: Scale up: meeting targets in global tuberculosis control. Lancet 2004, 363:814-819. (Pubitemid 38315173)
4. Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rüsch-Gerdes S, Varaine F: Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis 2005, 9:1147-1154. (Pubitemid 41433805)
5. Global Plan to Stop TB 2006-2015. Stop TB Partnership and World Health Organization. Geneva, World Health Organization; 2006, (WHO/HTM/STB/2006.35).
6. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV: The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics 1995, 96:29-35.
7. Rodrigues LC, Diwan VK, Wheeler JG: Protective effect of BCG against tuberculous meningitis and military tuberculosis: a meta-analysis. Int J Epidemiol 1993, 22:1154-1158. (Pubitemid 24025695)
8. Skeiky YA, Sadoff JC: Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006, 4:469-476. (Pubitemid 43771866)
9. Menzies D: A survey of vaccine technology. Presentation at 36th Union World Conference on lung health, Paris, France 2005.
10. UNAIDS. 2006 Report on the global AIDS epidemic [http://www.unaids.org/ en/KnowledgeCentre/HIVData/GlobalReport/2006/default.asp].
11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the Panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253-1258. (Pubitemid 26337709)
12. Brewer TF: Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000, 31(Suppl 3):64-67.
13. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
14. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Salgado AC, Jacquet V, Maloney S, Laserson K, Mendez AP, Menzies D: Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005, 353:1008-1020. (Pubitemid 41262335)
15. Jacquet V, Morose W, Schwartzman K, Oxlade O, Barr G, Grimard F, Menzies D: Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. BMC Public Health 2006, 6:209.
16. Styblo K: The relationship between the risk of tuberculosis infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc 1985, 60:117-119.
17. Sutherland I: The evolution of clinical tuberculosis in adolescents. Tuberc 1966, 47:308.
18. Nolan CM, Elarth AM: Tuberculosis in a cohort of Southeast Asian refugees. A five-year surveillance study. Am Rev Respir Dis 1988, 137:805-809.
19. Comstock GW, Edwards LB, Livesay VT: Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974, 110:572-580.
20. Burgess AL, Fitzgerald DW, Severe P, Joseph P, Noel E, Rastogi N, Johnson WD Jr, Pape JW: Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. AIDS 2001, 15:1875-79. (Pubitemid 32939250)
21. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum TN, Brassard P, Menzies D: Comparison of cost effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000, 162:2079-2086. (Pubitemid 32054359)
22. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA: HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002, 16:597-603.
23. Wood R, Maartens G, Lombard CJ: Risk factors for developing tuberculosis in HIV-1-infected adults from communities with low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000, 23:75-80. (Pubitemid 30123268)
24. Murray J, Sonnenberg P, Shearer SC, Godgrey-Faussett P: Human immunodeficiency virus and outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999, 159:733-740. (Pubitemid 29137767)
25. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD: An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New Engl J Med 1992, 326:1514-1521.
26. Malkin JE, Prazuck T, Simonnet F, Yameogo M, Rochereau A, Ayerour J, Masson D, Lafaix C: Tuberculosis and human immunodeficiency virus infection in West Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997, 1:68-74. (Pubitemid 127509689)
27. Aspler A, Menzies D, Oxlade O, Banda J, Mwenge L, Godfrey-Faussett P, Ayles H: Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis 2008, 12:928-935.
28. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR: Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999, 3:1088-1095.
29. Yamasaki-Nakagawa M, Ozasa K, Yamada N, Osuga K, Shimouchi A, Ishikawa N, Bam DS, Mori T: Gender difference in delays to diagnosis and health care seeking behaviour in a rural area of Nepal. Int J Tuberc Lung Dis 2001, 5:24-31. (Pubitemid 32401872)
30. Wandwalo ER, Morkve O: Delay in tuberculosis case-finding and treatment in Mwanza, Tanzania. Int J Tuberc Lung Dis 2000, 4:133-138. (Pubitemid 30123646)
31. Vaca J, Peralta H, Gresely L, Cordova R, Kuffo D, Romero E, Tannenbaum TN, Houston S, Graham B, Hernandez L, Menzies D: DOTS implementation in a middle-income country: development and evaluation of a novel approach. Int J Tuberc Lung Dis 2005, 9:521-527. (Pubitemid 40646837)
32. U.S. Department of Labor Statistics. Consumer price index 2007 [http://www.stats.bls.gov].
33. Stop TB Partnership Global Drug Facility: Stop TB Partnership. First-Line tuberculosis drugs & formulations currently supplied/to be supplied by the global TB drug facility, Geneva 2007 [http://www.stoptb.org/gdf/].
34. World Health Organization. Vaccine Preventable Diseases Monitoring System 2007 [http://www.who.int/vaccines/globalsummary/immunization/ countryprofileselect.cfm].
35. Baumann S, Nasser Eddine A, Kaufmann SH: Progress in tuberculosis vaccine development. Curr Opin Immunol 2006, 18:438-448, Epub 2006 Jun 13. (Pubitemid 43947587)
36. Ziv E, Daley CL, Blower S: Potential public health impact of new tuberculosis vaccines. Emerg Infect Dis 2004, 10:1529-1535. (Pubitemid 39201502)
37. Bhunu CP, Garira W, Mukandavire Z, Magombedze G: Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control. Journal of Theoretical Biology 2008, 254:633-649.
38. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C, Halloran ME: Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009, 106:13980-13985, Epub 2009 Aug 3.
39. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, Harrison LH: Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004, 291:2086-2091. (Pubitemid 38580151)
40. Fine PE: Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
41. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Hill AV, McShane H: Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009, 179:724-733.
42. Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A: Immunological conditions of children with BCG disseminated infection. Lancet 1995, 346:581.
43. WHO: Revised BCG vaccination guidelines for infants at risk for HIV infection. Weekly Epidemiological Record 2007, 82:193-196.
44. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, Beyers N: The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25:14-18, Epub 2006 Aug 1. (Pubitemid 44855247)
45. Brisson M, Edmunds WJ: Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making 2003, 23:76-82. (Pubitemid 36133362)
46. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM: Boosting vaccine for tuberculosis. Infect Immun 2001, 69:2714-2717. (Pubitemid 32239748)
47. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV: Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171:1602-1609. (Pubitemid 36900097)
48. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z: Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173:6357-6365. (Pubitemid 39487795)
49. Cohen T, Colijn C, Murray M: Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. PNAS 2008, 105:16302-16307.
50. van Leth F, van der Werf MJ, Borgdorff MW: Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ 2008, 86:20-26.
51. Egwaga SM, Cobelens FG, Muwinge H, Verhage C, Kalisvaart N, Borgdorff MW: The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 2006, 20:915-921. (Pubitemid 43731575)
52. Fletcher HA, Hawkridge T, McShane H: A new vaccine for Tuberculosis: The challenges of development and deployment. J Bioeth Inq 2009, 6:219-228.
53. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A: Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009, 9:162-72.
54. Aagaard C, Dietrich J, Doherty M, Andersen P: TB vaccines: current status and future perspectives Immunol Cell Biol. 2009, 87:279-286, Epub 2009 Apr 7.
55. Working Group on new TB Vaccines: Stop TB Partnership. TB Vaccine Pipeline 2009 [http://www.stoptb.org/wg/new-vaccines/assets/documents/ TB%20Vaccine%20Pipeline%2009%20final.pdf].
56. United Nations Populations Division. World population prospects: the 2006 revision [http://esa.un.org/unpp/].
57. CIA - The World Factbook. The World Factbook. Zambia 2007 [https://www.cia.gov/library/publications/the-world-factbook/geos/za.html].
58. The World Bank Group. Zambia Data Profile 2007 [http://web.worldbank. org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/ZAMBIAEXTN/0,,menuPK:375673~pagePK: 141159~piPK:141110~theSitePK:375589,00.html].
59. World Health Organization. Life tables for WHO member states 2007 [http://www.who.int/whosis/database/life-tables/life-tables.cfm].
60. Anti-tuberculosis drug resistance in the world. WHO report 2004, Geneva 2004.
61. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C: Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485. (Pubitemid 44162659)
62. Deschamps MM, Fitzgerald DW, Pape JW, Johnson WD Jr: HIV infection in Haiti: natural history and disease progression. AIDS 2000, 14:2515-2521.
63. Grzybowski S, Barnett GD, Styblo K: Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975, 50:90-106.
64. Menzies D: Issues in the management of contacts of patients with active pulmonary tuberculosis. Can J Public Health 1997, 88:197-201.
65. Stead WW: Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med 1995, 122:906-12.
66. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. Engl J Med 1997, 337:801-808. (Pubitemid 27391629)
67. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, Miro JM, Mallolas J, Zamora L, Gonzalez J, Sorano E: A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345-1349. (Pubitemid 23330305)
68. Beck-Sagué C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, Pitchenik AE, Woodley C, Cauthen G, Jarvis WR: Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992, 268:1280-1286.
69. Fischl MA, Uttamchandani RB, Daikos GL, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Lai S: An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992, 117:177-183.
70. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK: Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993, 328:1137-1144. (Pubitemid 23105750)
71. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, Hopewell PC: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231-235.
72. Grzybowski S, Enarson DA: The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc 1978, 53:70-74.
73. Horwitz O: Public health aspects of relapsing tuberculosis. Am Rev Respir Dis 1969, 99:183-193.
74. Reider HL: Epidemiologic basis of tuberculosis control. Paris, France, International Union Against Tuberculosis and Lung Disease;, First 1999, 1-162.
75. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA: A 62-dose, 6- month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990, 112:407-415.
76. East African Tuberculosis Investigation Centre, British Medical Research Council Tuberculosis and Chest Diseases Unit: Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977, 116:3-8.
77. Somner AR: Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic Association (third report). Lancet 1980, 1:1182-1183.
78. Algerian Working Group, British Medical Research Council: Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 1984, 129:921-928.
79. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S, Tuberculosis Trials Consortium: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360:528-534.
80. Chee CBE, Boudville IC, Chan SP, Zee YK, Wang YT: Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit - a one-year retrospective survey. Int J Tuber Lung Dis 2000, 4:496-503. (Pubitemid 30409165)
81. Parthasarathy R, Prabhakar R, Somasundaram PR: A controlled clinical trial of 3- and 5- month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 1986, 134:27-33. (Pubitemid 16057455)
82. East African Tuberculosis Investigation Centre, British Medical Research Council: Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: Second report of the 4th study. Am Rev Respir Dis 1981, 123:165-170.
83. Singapore Tuberculosis Service, British Medical Research Council: Long-term Follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:779-83.
84. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC: Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545. (Pubitemid 30324196)
85. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC: Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006, 12:1389-1397. (Pubitemid 44455215)
86. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA: Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996, 154:1034-1038.
87. Desvarieux M, Hyppolite PR, Johnson WD Jr, Pape JW: A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area. Am J Public Health 2001, 91:138-141. (Pubitemid 32049284)
88. Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, Milberg J, Aisu T, Whalen CC, Mugerwa RD, Ellner JJ: Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997, 1:446-453. (Pubitemid 127509629)
89. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P: HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001, 358:1687-1693. (Pubitemid 33124328)
90. Pulido F, Peña JM, Rubio R, Moreno S, González J, Guijarro C, Costa JR, Vázquez JJ: Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997, 157:227-231.
91. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP: Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 1998, 157:1249-1252.
92. Roos BR, van Cleeff MRA, Githui WA, Kivihya-Ndugga L, Odhiambo JA, Kibuga DK, Klatser PR: Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. Int J Tuber Lung Dis 1997, 2:235-241. (Pubitemid 28123524)
93. Trunz BB, Fine P, Dye C: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.